Abbvie Stock News

BME focuses on an underlying portfolio of healthcare stocks with a covered call strategy. Click here to see BME's holdings, performance, and my recommendation.

Dividend Kings have a remarkable track record of 50 or more years of increasing dividend payouts. Click here to learn more.

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. Read on.

Las Vegas, USA, March 15, 2022 (GLOBE NEWSWIRE) -- Breast Implants Market is Contemplated to Surge at a Tremendous CAGR of 7.00% by 2026, Asserts DelveInsight The increase in demand for Breast Implants is predominantly attributed to the growing prevalence of breast cancer among the population across the globe. In addition, the rising number of people demanding cosmetic surgeries mainly women to enhance their aesthetic appeal could also be a potential factor for increasing the Breast Implants market. Moreover, an increase in the number of breast augmentation surgeries and technological advancement in the product portfolio is expected to bolster the Breast Implant market during the forecasted period. DelveInsight''s Breast Implants Market Insights and Forecast report provides the current and forecast of Breast Implants, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Breast Implants Market scenario.

Dallas, March 11, 2022 (GLOBE NEWSWIRE) -- As per the report published by The Brainy Insights, the global inflammatory bowel disease treatment market is expected to grow from USD 18.47 billion in 2020 to USD 28.96 billion by 2030, at a CAGR of 4.6% during the forecast period 2021-2030. Inflammatory bowel disease (IBD) is a term for illnesses involving chronic inflammation of the digestive tract. Some common symptoms of IBD are: abdominal pain, weight loss, persistent diarrhea, rectal bleeding and fatigue. Ulcerative colitis and Crohn''s disease are the two most common kinds of IBD. The colon or large intestine are the only parts of the body affected by ulcerative colitis. On the other hand, Crohn''s disease can affect any portion of the gastrointestinal tract, from the mouth to the anus. The last part of the small intestine or the colon, or both, are the most usually affected areas. Anti-inflammatory drugs are frequently used as the first line of treatment against inflammatory bowel disease.

AbbVie Inc (NYSE: ABBV ) and Gedeon Richter Plc have announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter … Full story available on Benzinga.com

AbbVie (ABBV) and Gedeon Richter entered a new co-development and license agreement to develop and commercialize novel dopamine receptor modulators for the potential treatment…

AbbVie Inc (NYSE: ABBV ) has reported data from the Phase 3 PROGRESS trial of atogepant (Qulipta) for the preventive treatment of chronic migraine in adults . The trial met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to … Full story available on Benzinga.com

AbbVie (ABBV) said on Thursday that its Phase 3 trial for migraine therapy atogepant met the primary endpoint among adult patients suffering from the chronic form of the disease

NORTH CHICAGO, Ill., March 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the Phase 3 PROGRESS trial evaluating atogepant (QULIPTA™ in the United States), an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the preventive treatment of chronic…

Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV ), allowing Alvotech to market AVT02 (100 mg/mL), its high-concentration, citrate-free biosimilar adalimumab that references Humira, in the U.S. The settlement fully resolves all pending U.S. disputes between the two companies related to the adalimumab biosimilar, including the International Trade Commission (ITC) case filed in December 2021. AbbVie alleged that Alvotech developed AVT02 … Full story available on Benzinga.com

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc. (NYSE: ABBV ) and Alvotech announced a settlement agreement that gives Alvotech non-exclusive rights to market AVT01, a biosimilar to AbbVie''s Humira, in the U.S. The settlement gives Alvotech a license entry date into the U.S. of July 1, 2023. In February, the Food and Drug Administration accepted Alvotech''s biologic license application for ATV02, with the application including new data supporting interchangeability between ATV02 and Humira. AbbVie shares were adding 1.19% to $148.90 in premarket trading. NRx Pharma Founder & CEO Jonathan Javitt Retires NRx Pharmaceuticals, Inc. (NASDAQ: NRXP ) announced that Jonathan Javitt, the biopharma''s founder, has retired as chief executive officer, effective immediately. The board appointed Robert Besthof, Head of Operations and chief commercial officer, as Interim CEO.

AbbVie (ABBV) has entered into an agreement with Alvotech Holdings to resolve the U.S

As in the settlements AbbVie reached with several other drug makers, Alvotech cannot market its version of the rheumatoid arthritis drug until next year — in this case, no sooner…

The settlement is only the latest deal in which AbbVie has successfully delayed would-be rivals from marketing their own versions of the blockbuster drug.